[go: up one dir, main page]

AR076267A1 - Combinaciones de inhibidor de vhc y agentes terapeuticos. metodo. uso. - Google Patents

Combinaciones de inhibidor de vhc y agentes terapeuticos. metodo. uso.

Info

Publication number
AR076267A1
AR076267A1 ARP100101148A ARP100101148A AR076267A1 AR 076267 A1 AR076267 A1 AR 076267A1 AR P100101148 A ARP100101148 A AR P100101148A AR P100101148 A ARP100101148 A AR P100101148A AR 076267 A1 AR076267 A1 AR 076267A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
amino
heteroaryl
aryl
Prior art date
Application number
ARP100101148A
Other languages
English (en)
Original Assignee
Ptc Therapeutics Inc
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc, Schering Corp filed Critical Ptc Therapeutics Inc
Publication of AR076267A1 publication Critical patent/AR076267A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Producto combinado para tratar o mitigar la infeccion por virus de hepatitis C (VHC) o los trastornos o síntomas asociados con la misma en un sujeto que lo necesita que comprende, un inhibidor del VHC y uno o más agentes terapéuticos seleccionados entre cualquiera de los dos o ambos de los siguientes: un inhibidor de la proteasa del VHC y uno o más agentes terapéuticos diferentes administrados en combinacion en una cantidad eficaz al sujeto. Reivindicacion 2: El producto de acuerdo con la reivindicacion 1, donde el inhibidor del VHC de la reivindicacion 1 o un enantiomero, estereoisomero, diastereomero, racemato, tautomero, éster, prodroga, solvato, hidrato, isotopologo o forma de sal del mismo es un compuesto de Formula (1): donde W1, W2, W3, W4 son cada uno seleccionados entre N o C-R1; donde N puede ser opcionalmente sustituido con un átomo de O para formar un N-oxido y, donde al menos uno y hasta tres de W1, W2, W3 y W4 son N y el resto son C-R1; X es hidrogeno, halogeno, ciano, nitro, carboxilo, alquil C1-8-carbonilo, alcoxiC1-8-carbonilo, formilo, amino, alquiIC1-8-amino, amino-carbonilo, alquil C1-8-amino-carbonilo o alquilC1-8-sulfonilo; Y es arilo, heterociclilo, heteroarilo o heteroaril-1-oxido cada uno sustituido con un sustituyente seleccionado entre -N(R2)-SO2-R3, -SO2-N(R4)-R5, -SO2-R6, -N(H)-R2, -N(R2)-C(O)-N(H)-R4 o -N(R2)-C(O)-R3, donde arilo, heterociclilo o heteroarilo son opcionalmente sustituidos, individualmente, con uno o dos sustituyentes adicionales seleccionados independientemente entre halogeno, alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, amino o alquil C1-8-amino; Z es alquilo C1-8, alquenilC2-8- alquilo C1-8, alquinil C2-8-alquilo C1-8, halo-alquiloC1-8, alcoxi-C1-8alquiIo C1-8, alcoxiC1-8-carbonilo, carboxilo, cicloalquilo C3-14, cicloalquenilo C3-14, cicloalquil C3-14- alquilo C1-8, arilo, aril- alquilo C1-8, heteroarilo, heteroaril-alquilo C1-8, heterociclilo o heterociclil-alquilo C1-8, donde cada aparicion de arilo y heterorilo es opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes cada uno seleccionado entre hidroxi, ciano, nitro, halogeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, hidroxi-alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, amino, alquil C1-8-amino, alcoxi-C1-8alquilo C1-8, alquiltioC1-8, alquilC1-8-carbonilo, alcoxiC1-8-carbonilo, alquil C1-8-carboniloxi o amino-sulfonilo; R1 es seleccionado independientemente entre hidrogeno, halogeno, hidroxi, ciano, nitro, alquilo C1-8, hidroxi-alquilo C1-8, halo-alquilo C1-8, alquenilo C2-8, halo-alquenilo C2-8, alcoxi C1-8, halo-alcoxi C1-8, alcoxi-C1-8alquiloC1-8, alquilC1-8-carbonilo, alcoxi C1-8-carbonilo, alquil C1-8-carboniloxi, alquil C1-8-carboniloxi-alquilo C1-8, alquil C1-8-carboniloxi- alcoxi C1-8, amino, alquil C1-8-amino, amino-alquilo C1-8, alquil C1-8-amino- alquilo C1-8, (aril-alquilC1-8)(alquilC1-8)amino, amino- alcoxi C1-8, alquil C1-8-amino-alcoxi C1-8, alcoxi C1-8-alquil C1-8-amino- alcoxi C1-8, amino- alquil C1-8-amino- alcoxi C1-8, alquil C1-8-amino- alquil C1-8-amino- alcoxi C1-8, alcoxi C1-8-carbonil-amino, carboxil-amino, amino-carbonilo, amino-carbonil-amino, alquil C1-8-amino-carbonil-amino, alquiltio C1-8, alquil C1-8-sulfonilo, alquil C1-8-sulfiniIo, alquil C1-8-sulfonil-amino, cicloalquilo C3-14, cicloalquil C3-14-alquiIo C1-8, cicloalquil C3-14-alcoxi C3-14, cicloalquiloxiC3-14, arilo, aril-alquilo C1-8, aril-alcoxi C1-8, ariloxi, aril-carbonil-amino, heteroarilo, heteroaril-alquilo C1-8, heteroaril-alcoxi C1-8, heteroariloxi, heterociclilo, heterociclil-alquilo C1-8, heterociclil-alcoxi C1-8, heterocicliloxi o heterociclil- carboniloxi, donde en cada caso cicloalquilo C3-14, arilo, heteroarilo y heterociclilo está opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes cada uno seleccionado entre halogeno, ciano, alquilo C1-8, alcoxi C1-8, alcoxi C1-8 alquilo C1-8, amino, alquil C1-8-amino, amino-alquilo C1-8 o alquil C1-8-amino-alquilo C1-8; R2 es hidrogeno o alquilo C1-8, opcionalmente sustituido en el alquilo C1-8 con uno o más sustituyentes cada uno seleccionado entre halogeno, hidroxi, ciano, alcoxi C1-8, amino o alquil C1-8-amino; R3 es alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, cicloalquilo C3-14, cicloalquil C3-14-alquiIo C1-8, arilo, aril-alquilo C1-8, heteroarilo, heteroaril-alquilo C1-8, heterociclilo o heterociclil-alquilo C1-8, donde cada uno de arilo, heteroarilo, heterociclilo y cicloalquilo C3-14 es opcionalmente sustituido con uno o dos sustituyentes cada uno seleccionado entre halogeno, alquilo C1-8, halo- alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, amino o alquil C1-8-amino; R4 es hidrogeno o alquilo C1-8, opcionalmente sustituido en el alquilo C1-8 con uno o más sustituyentes cada uno seleccionado entre halogeno, hidroxi, ciano o alcoxi C1-8; R5 es hidrogeno, alquilo C1-8, hidroxi-alquilo C1-8, halo-alquilo C1-8, ciano- alquilo C1-8, alcoxi C1-8-alquilo C1-8, amino-alquilo C1-8, alquil C1-8-amino- alquilo C1-8, alquil C1-8-carbonilo, alcoxi C1-8-carbonilo, cicloalquilo C3-14, cicloalquil C3-14-alquilo C1-8, arilo, aril-alquilo C1-8, heteroarilo, heteroaril-alquilo C1-8, heterociclilo o heterociclil-alquilo C1-8, donde cada uno de arilo, heteroarilo, heterociclilo y cicloalquilo C3-14 es opcionalmente sustituido con uno o dos sustituyentes cada uno seleccionado entre halogeno, alquilo C1-8, halo-alquilo C1-8 alcoxi C1-8, halo-alcoxi C1-8, amino o alquil C1-8-amino; y R6 es alquilo C1-8, cicloalquilo C3-14, cicloalquil C3-14-aIquilo C1-8, arilo, aril- alquilo C1-8, heteroarilo, heteroaril-alquilo C1-8, heterociclilo o heterociclil- alquilo C1-8, donde cada uno de arilo, heteroarilo, cicloalquilo C3-14 y heterociclilo es opcionalmente sustituido con uno o dos sustituyentes cada uno seleccionado entre halogeno, alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, amino o alquilC1-8-amino. Reivindicacion 6: El producto de acuerdo con la reivindicacion 1, donde el inhibidor de la proteasa del VHC se selecciona entre un inhibidor de la NS2 proteasa, un inhibidor de la NS3 proteasa, un inhibidor de la NS3 proteasa peptídico o dipeptídico o un inhibidor del cofactor de la NS4a proteasa.
ARP100101148A 2009-04-06 2010-04-06 Combinaciones de inhibidor de vhc y agentes terapeuticos. metodo. uso. AR076267A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16691309P 2009-04-06 2009-04-06

Publications (1)

Publication Number Publication Date
AR076267A1 true AR076267A1 (es) 2011-06-01

Family

ID=42637072

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101148A AR076267A1 (es) 2009-04-06 2010-04-06 Combinaciones de inhibidor de vhc y agentes terapeuticos. metodo. uso.

Country Status (5)

Country Link
US (1) US9198907B2 (es)
EP (1) EP2416772A1 (es)
AR (1) AR076267A1 (es)
TW (1) TWI414288B (es)
WO (1) WO2010117936A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307419B1 (en) 2008-06-24 2013-11-06 Codexis, Inc. Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
WO2010117935A1 (en) * 2009-04-06 2010-10-14 Schering Corporation Compounds and methods for antiviral treatment
BR112014000314A2 (pt) 2011-07-08 2017-01-10 Novartis Ag derivados de pirrolo pirimidina
TW201318637A (zh) * 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
WO2013045668A2 (en) * 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
DE102013014881B4 (de) 2012-09-12 2023-05-04 Fairchild Semiconductor Corporation Verbesserte Silizium-Durchkontaktierung mit einer Füllung aus mehreren Materialien
NZ724878A (en) 2014-05-01 2019-03-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
DE69709671T2 (de) 1996-10-18 2002-08-22 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
AR021876A1 (es) * 1998-12-18 2002-08-07 Schering Corp Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
WO2004093812A2 (en) * 2003-04-22 2004-11-04 Irm Llc Compounds that induce neuronal differentiation in embryonic stem cells
AR049635A1 (es) * 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
KR20070083484A (ko) * 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Ｃ형 간염 치료 방법
RU2382786C2 (ru) * 2004-12-24 2010-02-27 ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. Бициклические производные пиррола
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US20070274951A1 (en) * 2006-02-09 2007-11-29 Xiao Tong Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
JP2009528353A (ja) 2006-03-03 2009-08-06 シェーリング コーポレイション Ｈｃｖのプロテアーゼ阻害剤およびｉｒｅｓ阻害剤の医薬的組み合わせ
SG174772A1 (en) * 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
MX2010002318A (es) * 2007-08-29 2010-03-22 Schering Corp Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
WO2010003133A2 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
WO2010117935A1 (en) * 2009-04-06 2010-10-14 Schering Corporation Compounds and methods for antiviral treatment

Also Published As

Publication number Publication date
US20120087893A1 (en) 2012-04-12
EP2416772A1 (en) 2012-02-15
US9198907B2 (en) 2015-12-01
TWI414288B (zh) 2013-11-11
WO2010117936A1 (en) 2010-10-14
TW201102061A (en) 2011-01-16

Similar Documents

Publication Publication Date Title
AR076267A1 (es) Combinaciones de inhibidor de vhc y agentes terapeuticos. metodo. uso.
ECSP12012104A (es) Inhibidores de virus flaviviridae
AR076266A1 (es) Compuestos de azaindol, composiciones farmaceuticas y uso de los compuestos en el tratamiento de hcv
CY1109673T1 (el) Συνεργεια των gos και της πολυφρουκτοζης
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
BRPI0514425A (pt) inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos
AR076268A1 (es) Combinaciones de inhibidor de vhc y agentes terapeuticos. metodo. uso.
AR084393A1 (es) Metodos para tratar el virus de la hepatitis c, composicion, uso, combinacion, kit y uno o mas compuestos anti vhc
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
BRPI0517463A (pt) inibidores da protease do vìrus da hepatite c, composições e tratamentos usando os mesmos
EA201390822A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
UY30392A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
AR081261A1 (es) Metodos para tratar afecciones virales
ECSP066794A (es) Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
BR112014030639A2 (pt) inibidores macrocíclicos de vírus flaviviridae
BR112014030630A2 (pt) inibidores macrocíclicos de vírus flaviviridae
DK2203430T3 (da) N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
AR063942A1 (es) Compuestos de oximilo aciclico inhibidores de proteasa del virus de hepatitis c
EA201290575A1 (ru) Ингибиторы вирусов flaviviridae
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
CY1120435T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου
AR046959A1 (es) Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio

Legal Events

Date Code Title Description
FA Abandonment or withdrawal